Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
JNCI Cancer Spectrum|July 31, 2019
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-AnalysisHadar Goldvaser, Yasmin Korzets, Daniel Shepshelovich, et al.
Plos One|August 31, 2013
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisIrit Ben-Aharon, Liat Vidal, Shulamith Rizel, et al.
Cancer Medicine|May 7, 2020
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancerDaniel A Goldstein, Chen Mayer, Tzippy Shochat, et al.
Biomedicines|December 10, 2020
Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity-From Bench to BedsideMattan Levi, Tal Goshen-Lago, Rinat Yerushalmi, et al.
Frontiers in Medicine|August 20, 2021
Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting PeptideDanny Alon, Yossi Paitan, Eyal Robinson, et al.
Oncology Reports|November 21, 2008
Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanomaJair Bar, Rinat Yerushalmi, Roni Shapira-Frummer, et al.
American Journal of Clinical Oncology|January 11, 2011
Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized studyDaniel Hendler, Shulamith Rizel, Rinat Yerushalmi, et al.
Oncology Reports|June 18, 2002
Basic fibroblast growth factor mediated growth inhibition in breast cancer cells is independent of ras signaling pathwayEyal Fenig, Martin Szyper-Kravitz, Rinat Yerushalmi, et al.
Breast (Edinburgh, Scotland)|September 4, 2021
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancerRaz Mutai, Tamar Barkan, Assaf Moore, et al.
The Breast Journal|December 27, 2019
Intraoperative radiation therapy for breast cancer-Immediate and 30-month oncological outcomesIdit Melnik, Rinat Yerushalmi, Yael Sobol, et al.
Pageof 10